business
See 10% overall growth for Sun-Ranbaxy entity: Surajit Pal
or the investors who are holding the stock should continue to hold it but fresh entry should be made only if it corrects from the current levels, says Surajit Pal, pharma analyst at Prabhudas Lilladher.
first published: Mar 25, 2015 02:21 pm